Cargando…
DIPG-02. Role of a Bevacizumab-based regime in the treatment of children with diffuse intrinsic pontine glioma (DIPG): a systematic review
BACKGROUND: Diffuse intrinsic pontine glioma (DIPG) is an aggressive paediatric brainstem tumour. There are no effective treatments and median survival is 11.2 months, therefore maintaining quality of life (QOL) is a priority for many families. Bevacizumab, an anti-VEGF IgG antibody, has the potenti...
Autores principales: | Evans, Mia, Gill, Ria, Bull, Kim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164908/ http://dx.doi.org/10.1093/neuonc/noac079.059 |
Ejemplares similares
-
DIPG-02. USEFULNESS OF BEVACIZUMAB IN MAINTAINING QUALITY OF LIFE AT THE TIME OF DIFFUSE INTRINSIC PONTINE GLIOMA RELAPSE
por: Gomi, Akira, et al.
Publicado: (2020) -
DIPG-40. TARGETING MASTER REGULATOR DEPENDENCIES IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Pavisic, Jovana, et al.
Publicado: (2020) -
DIPG-01. REIRRADIATION PRACTICES FOR DIFFUSE INTRINSIC PONTINE GLIOMA
por: Cacciotti, Chantel, et al.
Publicado: (2020) -
DIPG-32. AKT SIGNALING DRIVES RESISTANCE TO ONC201 IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Jackson, Evangeline R, et al.
Publicado: (2020) -
DIPG-27. Behavioral disturbances as underestimated presenting symptoms in children with Diffuse Intrinsic Pontine Glioma (DIPG)
por: Milanaccio, Claudia, et al.
Publicado: (2022)